Literature DB >> 17023981

Molecular genetics and related developments in pancreatic cancer.

R H Hruban1, M Goggins, S E Kern.   

Abstract

Cancer of the pancreas is a genetic disease. The most common genetic alterations identified to date in pancreatic cancer are activation of the K-ras oncogene (approximately 90%) and inactivation of the p16 (approximately 95%), p53 (50% to 75%), DPC4 (55%), and BRCA2 (7%) tumor suppressor genes. An understanding of the molecular genetics of carcinoma of the pancreas is important because it may help explain the aggregation of pancreatic cancer in families and may lead to the development of novel tests to detect early cancers. For example, the aggregation of pancreatic cancer in some families has been shown to result from inherited mutations in cancer-causing genes, and genetic alterations shed from pancreatic cancers have been detected in stool specimens. In addition, we believe that an improved knowledge of the molecular genetics of pancreatic cancer will lead to the development of a new generation of rational and more effective treatments.

Entities:  

Year:  1999        PMID: 17023981     DOI: 10.1097/00001574-199909000-00006

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  9 in total

1.  Diagnostic and therapeutic implications of a novel immunohistochemical panel detecting duodenal mucosal invasion by pancreatic ductal adenocarcinoma.

Authors:  Sabrina C Sopha; Purva Gopal; Nipun B Merchant; Frank L Revetta; David V Gold; Kay Washington; Chanjuan Shi
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

2.  Impact of Sixteen Established Pancreatic Cancer Susceptibility Loci in American Jews.

Authors:  Samantha A Streicher; Alison P Klein; Sara H Olson; Laufey T Amundadottir; Andrew T DeWan; Hongyu Zhao; Harvey A Risch
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-07-28       Impact factor: 4.254

3.  Ikaros directly represses the notch target gene Hes1 in a leukemia T cell line: implications for CD4 regulation.

Authors:  Katie L Kathrein; Sheila Chari; Susan Winandy
Journal:  J Biol Chem       Date:  2008-02-20       Impact factor: 5.157

4.  Loss of the transcription factor GLI1 identifies a signaling network in the tumor microenvironment mediating KRAS oncogene-induced transformation.

Authors:  Lisa D Mills; Yaqing Zhang; Ronald J Marler; Marta Herreros-Villanueva; Lizhi Zhang; Luciana L Almada; Fergus Couch; Cynthia Wetmore; Marina Pasca di Magliano; Martin E Fernandez-Zapico
Journal:  J Biol Chem       Date:  2013-03-12       Impact factor: 5.157

5.  Pancreatic adenocarcinoma: new strategies for success.

Authors:  Eileen M O'Reilly
Journal:  Gastrointest Cancer Res       Date:  2009-03

6.  A study of Smad4, Smad6 and Smad7 in Surgically Resected Samples of Pancreatic Ductal Adenocarcinoma and Their Correlation with Clinicopathological Parameters and Patient Survival.

Authors:  Puneet Singh; Radhika Srinivasan; Jai Dev Wig; Bishan Das Radotra
Journal:  BMC Res Notes       Date:  2011-12-23

7.  ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors.

Authors:  Freddy E Escorcia; Jacob L Houghton; Dalya Abdel-Atti; Patricia R Pereira; Andrew Cho; Nicholas T Gutsche; Kwamena E Baidoo; Jason S Lewis
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

8.  Racial/ethnic disparities in weight or BMI change in adulthood and pancreatic cancer incidence: The multiethnic cohort.

Authors:  Albert J Farias; Samantha A Streicher; Daniel O Stram; Songren Wang; Stephen J Pandol; Loïic Le Marchand; Veronica W Setiawan
Journal:  Cancer Med       Date:  2021-05-16       Impact factor: 4.452

9.  Screening technologies for target identification in pancreatic cancer.

Authors:  Patrick Michl; Stefanie Ripka; Thomas Gress; Malte Buchholz
Journal:  Cancers (Basel)       Date:  2010-12-29       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.